BACKGROUND: A role for inflammation, and consequently of non-steroidal anti-inflammatory drugs, in ovarian carcinogenesis has been proposed, but epidemiological evidence is scanty. PATIENTS AND METHODS: Data were derived from a hospital-based case-control study conducted in Italy between 1992 and 1999. Cases were 749 women, aged 18-80 years (median age 56 years), with incident, histologically confirmed ovarian cancer. Controls were 898 non-hysterectomized women, aged 17-80 years (median age 58 years), admitted to hospital for acute conditions, unrelated to risk factors for ovarian cancer. RESULTS: The multivariate odds ratio (OR) was 0.93 (95% confidence interval (95% CI): 0.53-1.62) for regular aspirin use for more than six months, 1.38 (95% CI: 0.57-3.36) for current use and 0.72 (95% CI: 0.35-1.47) for former use. The OR was not significantly different from unity for duration of use, age at starting use, indication (analgesia or cardiovascular prevention), and in women aged < 60 and > or = 60 years at ovarian cancer diagnosis. CONCLUSIONS: This study provides little support for the hypothesis that aspirin may reduce the risk of ovarian cancer.
BACKGROUND: A role for inflammation, and consequently of non-steroidal anti-inflammatory drugs, in ovarian carcinogenesis has been proposed, but epidemiological evidence is scanty. PATIENTS AND METHODS: Data were derived from a hospital-based case-control study conducted in Italy between 1992 and 1999. Cases were 749 women, aged 18-80 years (median age 56 years), with incident, histologically confirmed ovarian cancer. Controls were 898 non-hysterectomized women, aged 17-80 years (median age 58 years), admitted to hospital for acute conditions, unrelated to risk factors for ovarian cancer. RESULTS: The multivariate odds ratio (OR) was 0.93 (95% confidence interval (95% CI): 0.53-1.62) for regular aspirin use for more than six months, 1.38 (95% CI: 0.57-3.36) for current use and 0.72 (95% CI: 0.35-1.47) for former use. The OR was not significantly different from unity for duration of use, age at starting use, indication (analgesia or cardiovascular prevention), and in women aged < 60 and > or = 60 years at ovarian cancer diagnosis. CONCLUSIONS: This study provides little support for the hypothesis that aspirin may reduce the risk of ovarian cancer.
Authors: Veronica Wendy Setiawan; Rayna K Matsuno; Galina Lurie; Lynne R Wilkens; Michael E Carney; Brian E Henderson; Laurence N Kolonel; Marc T Goodman Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-06-04 Impact factor: 4.254
Authors: Simone P Pinheiro; Margaret A Gates; Immaculata De Vivo; Bernard A Rosner; Shelley S Tworoger; Linda Titus-Ernstoff; Susan E Hankinson; Daniel W Cramer Journal: Int J Mol Epidemiol Genet Date: 2010-09-03
Authors: Takiko Daikoku; Dingzhi Wang; Susanne Tranguch; Jason D Morrow; Sandra Orsulic; Raymond N DuBois; Sudhansu K Dey Journal: Cancer Res Date: 2005-05-01 Impact factor: 12.701
Authors: Megan A Murphy; Britton Trabert; Hannah P Yang; Yikyung Park; Louise A Brinton; Patricia Hartge; Mark E Sherman; Albert Hollenbeck; Nicolas Wentzensen Journal: Cancer Causes Control Date: 2012-09-13 Impact factor: 2.506
Authors: Simone P Pinheiro; Shelley S Tworoger; Daniel W Cramer; Bernard A Rosner; Susan E Hankinson Journal: Am J Epidemiol Date: 2009-04-02 Impact factor: 4.897
Authors: Nitin Shivappa; James R Hébert; Valentina Rosato; Marta Rossi; Maurizio Montella; Diego Serraino; Carlo La Vecchia Journal: Cancer Causes Control Date: 2016-06-04 Impact factor: 2.506